
Groundbreaking news in the world of transfusions released from the CDC and AABB this week.
This is the nation’s first surveillance system to track adverse events in patients who receive blood transfusions, and the CDC is also encouraging healthcare facilities to utilize this new system.
Part of the CDC’s National Healthcare Safety Network, the new Hemovigilance Module is an Internet-based surveillance system that allows healthcare-associated infection data to be tracked and analyzed so the CDC and healthcare facilities can maximize prevention efforts. The CDC developed the system with AABB (American Assoc. of Blood Banks), an international association that represents people and institutions involved in activities related to transfusion and cellular therapies, including transplantation medicine.
Healthcare facilities that join the Hemovigilance Module will now have a mechanism by which to measure their current safety initiatives and their future efforts. Through this system, healthcare facilities can see how their performance stacks up to similar facilities nationwide, with a goal of designing the best processes to protect patients' health and reduce healthcare costs.
The CDC will provide the module at no cost to healthcare facilities, and will also provide training and ongoing user support at no charge to hospitals.
Currently, the US is the only developed country that does not have an established method to track and monitor adverse events associated with blood transfusion on a national level.
This is a fantastic advancement for the US and for transfusions recipients - we will have more confidence in the transfusion and a way to successfully track the transfused blood in case of any unforeseen event.






